2
Clinical Trials associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*0201 or HLA-A*0206 restricted epitope peptides URLC10 emulsified with Montanide ISA 51 for advanced non-small cell lung cancers.
Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
100 Clinical Results associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Translational Medicine associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Patents (Medical) associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Deals associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)